LB Pharmaceuticals Inc (LBRX)

LB Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	-	13.66	3.53
Research & Development	-	51.17	7.85
Operating Expenses	-	64.83	11.38
Operating Income	-	-64.83	-11.38
Interest Expense / Income	-	0	4.83
Other Expense / Income	-	-1.73	-9.93
Pretax Income	-	-63.1	-6.27
Income Tax	-	0	0
Net Income	-	-63.1	-6.28
Shares Outstanding (Basic)	3	10	8
Shares Outstanding (Diluted)	-	10	8
Shares Change	-66.26%	27.01%	-
EPS (Basic)	-	-6.20	-0.78
EPS (Diluted)	-	-6.20	-0.78
Free Cash Flow	-	-53.82	-12.12
Free Cash Flow Per Share	-	-5.29	-1.51
EBITDA	-	-62.7	-1.45
Depreciation & Amortization	-	0.4	0
EBIT	-	-63.1	-1.45

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).